This exactly means the difference between the AKI-induced intrinsic drug clearance differences (reductions) for patients with and without CYP2C9 polymorphism determines the direction and values of INTadd (AKI and CYP2C9). This evidence concerns the gene CYP2C9 and acute kidney injury.